Financial Performance - The company's revenue for Q1 2023 reached ¥1,134,403,107.24, representing a year-on-year increase of 30.43%[6] - Net profit attributable to shareholders was ¥155,850,307.28, marking a significant increase of 61.09% compared to the same period last year[6] - The basic earnings per share (EPS) for the quarter was ¥0.34, reflecting a growth of 61.9% year-on-year[7] - Operating profit for Q1 2023 was ¥170,949,622.20, up 64.8% from ¥103,598,487.16 in Q1 2022[22] - Net profit for Q1 2023 was ¥157,206,040.09, representing a 62.6% increase compared to ¥96,618,150.94 in Q1 2022[22] - Total revenue for Q1 2023 reached ¥1,134,403,107.24, a 30.5% increase from ¥869,770,720.65 in Q1 2022[21] - The company reported a total profit of ¥164,037,059.46 for Q1 2023, compared to ¥60,760,141.40 in Q1 2022, indicating strong financial performance[32] Cash Flow and Assets - The net cash flow from operating activities was ¥99,912,686.58, which is an increase of 105.39% compared to the previous year[6] - Operating cash flow for Q1 2023 was ¥955,357,247.48, an increase from ¥712,736,374.06 in Q1 2022[24] - Cash flow from operating activities for Q1 2023 was ¥98,805,509.39, significantly higher than ¥11,879,395.65 in Q1 2022[35] - The company reported a net cash outflow from investing activities of approximately ¥186.14 million, slightly improved from a net outflow of ¥196.19 million in Q1 2022[25] - The company reported a net cash outflow from investing activities of ¥183,974,699.16 in Q1 2023, an improvement from a net outflow of ¥204,594,844.55 in Q1 2022[35] - Total assets at the end of the reporting period amounted to ¥7,165,803,934.34, up 5.15% from the end of the previous year[7] - Total assets as of March 31, 2023, are ¥7,165,803,934.34, compared to ¥6,815,073,080.14 at the end of 2022[17] - Total current assets as of March 31, 2023, amount to ¥5,058,311,975.67, an increase from ¥4,744,959,783.92 as of December 31, 2022[16] - The company’s total equity as of March 31, 2023, was approximately ¥5.06 billion, up from ¥4.91 billion at the end of 2022, indicating a growth of 3.1%[29] Research and Development - The company's R&D expenses increased by 41.37% due to higher investment in new product development during the quarter[9] - Research and development expenses for Q1 2023 totaled ¥91,770,882.19, up 41.3% from ¥64,917,148.86 in Q1 2022[22] - Research and development expenses increased to ¥77,150,126.75 in Q1 2023, compared to ¥59,518,278.36 in Q1 2022, reflecting a focus on innovation[31] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,941[12] - The largest shareholder, Chenxin Technology Group Co., Ltd., holds 118,891,080 shares, accounting for 26.23% of total shares[12] Liabilities and Financial Position - Total liabilities increased to ¥1,649,732,207.11 from ¥1,459,249,793.23 year-over-year[17] - Total liabilities increased to ¥1.63 billion from ¥1.42 billion, marking a rise of 14.8% year-over-year[29] Inventory and Receivables - Accounts receivable increased to ¥735,505,457.86 from ¥716,164,071.35 year-over-year[16] - The company’s inventory increased to ¥551.78 million from ¥473.71 million, reflecting a rise of 16.5% year-over-year[27] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to sustain growth[9]
辰欣药业(603367) - 2023 Q1 - 季度财报